使用欧洲癌症研究与治疗组织（EORTC）风险表预测Ta T1期膀胱癌个体患者的复发和进展：来自七项EORTC试验的2596例患者的综合分析
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
作者信息
Sylvester Richard J, van der Meijden Adrian P M, Oosterlinck Willem, Witjes J Alfred, Bouffioux Christian, Denis Louis, Newling Donald W W, Kurth Karlheinz
机构信息
EORTC Data Center, Brussels, Belgium.
出版信息
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. doi: 10.1016/j.eururo.2005.12.031. Epub 2006 Jan 17.
OBJECTIVES
To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection.
METHODS
A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials.
RESULTS
A simple scoring system was derived based on six clinical and pathological factors: number of tumors, tumor size, prior recurrence rate, T category, carcinoma in situ, and grade. The probabilities of recurrence and progression at one year ranged from 15% to 61% and from less than 1% to 17%, respectively. At five years, the probabilities of recurrence and progression ranged from 31% to 78% and from less than 1% to 45%.
CONCLUSIONS
With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up.
目的
提供表格，使泌尿外科医生能够轻松计算经尿道切除术后浅表性膀胱癌患者复发和进展的短期及长期风险。
方法
对欧洲癌症研究与治疗组织七项试验纳入的2596例浅表性膀胱癌患者的个体患者数据进行综合分析。
结果
基于六个临床和病理因素得出一个简单的评分系统：肿瘤数量、肿瘤大小、既往复发率、T分期、原位癌和分级。一年时复发和进展的概率分别为15%至61%和小于1%至17%。五年时，复发和进展的概率分别为31%至78%和小于1%至45%。
结论
根据这些概率，泌尿外科医生可以与患者讨论不同的选择，以确定最合适的治疗方法和随访频率。
Zotero 插件